A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

NCT07794579 · Not yet recruiting

Last updated 2026-09-22

This study tests the investigational medication orforglipron in adults who are overweight and at risk of developing obesity-related health issues or progressing to a higher obesity class.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 2,001 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-09 · est. completion 2030-09

Where 179 sites · Argentina, China, Czechia, Germany, India, Japan, Mexico, Puerto Rico, South Korea, Spain, Taiwan, United States

What this study is testing ClinicalTrials.gov NCT07794579 ↗

Description as written by the study sponsor.

This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally
Placebo Drug

Administered orally

Main thing measured	Time to Onset of Obesity Related Complications or Class 1 Obesity
Sponsor	Eli Lilly and Company
Conditions studied	Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07794579 ↗